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ThematrixmetalloproteinasesMMP-9andMMP-2,majormodulatorsoftheextracellularmatrix(ECM),werechangedinamount
and distribution in the rat anteroventral cochlear nucleus (AVCN) following its sensory deaﬀerentation by cochlear ablation.
To determine what causal relationships exist between the redistribution of MMP-9 and MMP-2 and deaﬀerentation-induced
reinnervation, kainic acid was stereotaxically injected into the ventral nucleus of the trapezoid body (VNTB) prior to cochlear
ablation, killing cells that deliver the growth associated protein 43 (GAP-43) into AVCN. Deaﬀerentation-induced changes in the
pattern of MMP-9 staining remained unaﬀected by VNTB lesions. By contrast, changes in the distribution of MMP-2 normally
evoked by sensory deaﬀerentation were reversed if GAP-43 positive axons were prevented to grow in AVCN. In conclusion, GAP-
43-containing axons emerging in AVCN after cochlear ablation seem to be causal for the maintenance of MMP-2-mediated ECM
remodeling.
1.Introduction
Cochlear ablation entails Wallerian degeneration of the au-
ditory nerve ﬁbers and loss of their synaptic terminals in the
cochlear nucleus (CN) [1]. This lesion-induced detrimental
phase proceeds for some days, leaving the CN with a mas-
sively reduced input of excitatory aﬀerents [2, 3]. Subsequent
to the removal of degenerating axons and synaptic endings,
a constructive phase of tissue reorganization is initiated, ap-
parently comprising nervous regeneration and reinnervation
[4, 5].
The growth-associated protein 43 (GAP-43) is a marker
of axonal growth and synaptogenesis in the central nervous
system (CNS) [6]. Highly expressed during early brain on-
togeny, GAP-43 expression is turned down with the progres-
sion of postnatal development [6, 7] but stays high in some
cerebral regions or may rise again if network modiﬁcations
and synaptic remodeling are required [8, 9]. Following
sensory deaﬀerentation, GAP-43 reemerges in ﬁbers and
presynaptic terminals growing into the anteroventral CN
(AVCN) [10, 11]. These ﬁbers originate from neurons of the
medial olivocochlear (MOC) system arising in the ventral
nucleus of the trapezoid body (VNTB), a rhombencephalic
region characterized by conspicuously large cholinergic neu-
rons [10, 12]. On their way to the inner ear, MOC neurons
give oﬀ axon collaterals into the cochlear nucleus [13–15],
terminating in the marginally located granule cell layer of
AVCN in normal animals [16, 17]. These axon collaterals
sprout into central parts of AVCN upon cochlear ablation,
replacing the lost excitatory input of the auditory nerve [12].
In the present study GAP-43 was used as a marker for axonal
growth and reactive synaptogenesis.
Nerve degeneration and regeneration entail and require
extensive tissue dynamics which includes perishing of some
structural elements and formation of others, disappearance
of some molecular components and rise of others, and the
movement of membranes, organelles, and molecules, all af-
fecting diﬀerent types of cells and the extracellular matrix2 Neural Plasticity
Table 1: Experimental groups.
Group Surgical procedures POD following
cochlear ablation
Number of
brains Immunohistochemical procedures
1— — 5
GAP-43 ABC-DAB
MMP-2 ABC-DAB + ﬂat-embedding + semithin sectioning
MMP-9 ABC-DAB + ﬂat-embedding + semithin sectioning
2
PBS injection into VNTB
→ recovery for 1–3 weeks —2
GAP-43 ABC-DAB
MMP-2 ABC-DAB + ﬂat-embedding
MMP-9 ABC-DAB + ﬂat-embedding
KA injection into VNTB
→ recovery for 1–3 weeks —2
GAP-43 ABC-DAB
MMP-2 ABC-DAB + ﬂat-embedding
MMP-9 ABC-DAB + ﬂat-embedding
3 Cochlear ablation
POD1
POD3
POD7
4
3
5
GAP-43 ABC-DAB
MMP-2 ABC-DAB + ﬂat-embedding + semithin sectioning
MMP-9 ABC-DAB + ﬂat-embedding + semithin sectioning
4
KA injection into VNTB
→ recovery for 1-3 weeks
→ cochlear ablation
POD3
POD7
3 cL/2 iL
5 cL/3 iL
GAP-43 ABC-DAB
MMP-2 ABC-DAB + ﬂat-embedding
MMP-9 ABC-DAB + ﬂat-embedding
cL: complete lesion of VNTB; DAB: diaminobenzidine staining; iL: incomplete lesion of VNTB; KA: kainic acid; PBS: phosphate buﬀered saline; POD:
postoperative day.
(ECM). Matrix metalloproteinases (MMPs) are key modu-
lators of the ECM in nerve tissue. They constitute a large
family of mainly extracellularly operating enzymes [18]( f o r
exceptions see[19,20]).Theyaresynthesizedandsecretedas
inactiveproenzymesandactivatedinpericellularregions[17,
18] to perform essential functions in neuroplasticity and the
processes of Wallerian degeneration as well as axonal growth
and regeneration (for review see [21–23]). Besides serving
molecular signaling through the processing of ligands that
then bind to speciﬁc cell surface receptors, MMPs also func-
tion in the physical restructuring of the pericellular environ-
ment [24].
The gelatinases MMP-9 and MMP-2 belong to the most
abundantMMPswithin thebrain[25].Inanearlierstudywe
were able to show a spatiotemporal relationship of MMP-2
accumulationintheneuropilwiththeemergenceofGAP-43-
positive nerve ﬁbers andboutons inthe sensory-deaﬀerented
AVCN [26] and suggested MMP-2 to be involved in the com-
pensatory restructuring of neuronal networks that have suf-
fered a massive loss of synaptic contacts. The same cannot
be claimed of MMP-9. According to the literature, MMP-9 is
often associated with early tissue responses due to neurode-
generation and related events following injury like neuronal
death [27–29], glial scar formation [30], and opening of the
blood brain-barrier [29].
With the present study, we aimed to settle two issues.
First, we charted the staining pattern of MMP-9 and MMP-2
in AVCN at diﬀerent points in time following ablation of the
cochlea in order to see if their amount, distribution, or both
are changed as a consequence of sensory deaﬀerentation.
Sincewequicklynoticedthatlittlechangesoccurredinglobal
staining for either MMP (manuscript in preparation), but
that local changes centered around neuronal cell bodies were
obvious, we here focus on the MMP staining of neurons and
their surround. Second, we attempted to determine if there
is a causal relationship between the deaﬀerentation-induced
redistribution of the MMPs and reinnervation of AVCN. We
therefore lesioned VNTB prior to sensory deaﬀerentation to
prevent axonal sprouting and synaptogenesis in AVCN [12].
Deviations from the normal deaﬀerentation-induced redis-
tributions of MMP-9 and MMP-2 were documented.
2.ExperimentalProcedures
2.1. Animals. Brains of 34 female Wistar rats of ages 6 to
10 weeks were used in this study. Care and use of the ani-
mals as reported here were approved by the appropriate
agency (Regierungspr¨ asidium Freiburg, Germany, permis-
sion number 35/9185.81/G-07/22). For surgery, rats were
deeply anesthetized with an intraperitoneal injection of a
mixture of ketamine (50mg/kg, Ketanest, Parke-Davis, Ann
Arbor, Mich, USA) and xylazine (5mg/kg, Rompun, Bayer
Leverkusen, Germany). Animals were divided into 4 exper-
i m e n t a lg r o u p s( Table 1). Group 1 consisted of control ani-
mals that did not receive any surgery. Group 2 included ani-
mals receiving injections of phosphate buﬀered saline (PBS)
into VNTB and animals unilaterally injected with kainic acid
(KA) into VNTB. Animals in group 3 received a unilateral
cochlear ablation and survived for 1, 3, or 7 postoperative
days (PODs). Group 4 consisted of animals receiving KA
injections into VNTB on the right side of the brainstem
followed by cochlear ablation on the left side 1 to 3 weeks
later. After cochlear ablation, animals survived for 3 or 7
days (Table 1). Investigations at POD1 were not done in this
group because GAP-43 does not notably emerge in AVCN
beforePOD3[4].Throughoutthisstudy,thesideofthebrain
on which the cochlear ablation was done is referred to as
ipsilateral.
2.2. Cochlear Ablation. Following anesthesia (see above),
tympanic membranes were checked for integrity and trans-
parency. Unilateral cochlear ablation was performed on the
left side using a retroauricular approach [4]. After the facialNeural Plasticity 3
Table 2: Antibodies.
Antigen Immunogen Source Working dilution
Primary Antibodies
Growth associated protein 43
(GAP-43), clone 9-1E12
43-48 kDa GAP-43 (B-50, F1 or pp46)
puriﬁed from rat brain.
Millipore, Temecula, Calif, USA; mouse,
monoclonal, IgG1, cat.no. MAB347. 1:5,000
Matrix metalloproteinase 2
(MMP-2), clone H-76
raised against amino acids 1–76 of
MMP-2 of human origin.
Santa Cruz Biotechnology, Inc. Santa
Cruz, Calif, USA; rabbit, polyclonal, IgG,
cat.no. sc-10736.
1:100
Matrix metalloproteinase 9
(MMP-9) clone C-20
raised against a peptide mapping at the
C-terminus of MMP-9 of human origin.
Santa Cruz Biotechnology, Inc., Santa
Cruz, Calif, USA; goat, polyclonal, IgG,
cat.no. sc-6840.
1: 250
Secondary Antibodies
Horse anti-mouse biotinylated Mouse IgG Vector laboratories 1:200
Goat anti-rabbit biotinylated Rabbit IgG Vector laboratories 1:200
Rabbit anti-goat biotinylated Goat IgG Vector laboratories 1:200
nervewassectionedatitsexitfromtheskull,tympanicmem-
brane and ossicles were removed and the opening in the
bulla tympani was widened to provide good visibility of the
cochlea. The bony wall of the cochlea was opened with a dia-
mond drill and the interior of the cochlea, including the
spiral ganglion, was completely removed. Cochlea and bulla
were ﬁlled with Gelfoam (Marbagelan/Spongostan, Ferrosan
AS,Soeborg,Denmark)andthewoundwassurgicallyclosed.
2.3. Stereotaxic Injection of KA into VNTB. Animals were po-
sitionedinastereotaxicheadholder.Acraniotomywasmade
with a diameter of approximately 3mm and the dura mater
opened. The hole was centered at 2mm caudal and 2mm
lateral to point lambda [31]. A Hamilton syringe connected
to a glass micropipette with a tip diameter of approximately
50μm was used for unilateral (right) pressure injection of
KA (kainic acid monohydrate, Sigma-Aldrich, Taufkirchen,
Germany, K0250-10MG, 100nL per injection, 1mg/100μL
Locke’s solution). Injections were centered in VNTB with the
stereotaxictargetcoordinates1.8mmlateral,0.7mmventral,
and 0.3mm rostral to interaural zero in rats with a body
weight of approximately 200g. The injection lasted for 5min
and the pipette was left in position for another 5min before
withdrawal. The skull opening was covered with Gelfoam,
and the scalp was surgically closed. Rats recovered from
the injection before cochlear ablation on the opposite (left)
side or direct histological processing of their brains. Bilateral
injections of KA were not done for two reasons. First, the
crossed projection of MOC neurons residing in VNTB dom-
inates the uncrossed projection [13]. Correspondingly, ex-
periments with contralateral KA injection followed by
cochlear ablation showed a massive reduction of cochlear
ablation-induced GAP-43 expression in the AVCN [12].
Second, rats receiving bilateral KA injections into the rhom-
bencephalon large enough to cover VNTB have a low chance
of survival [12].
2.4. Immunohistochemistry. Animals received a lethal intra-
peritoneal dose of Trapanal (50mg in 1mL distilled water/
200g body weight, Nycomed GmbH, Konstanz, Germany)
and were perfused transcardially with a ﬁxation solution
containing 4% paraformaldehyde and 0.1% glutaraldehyde
in 0.1M phosphate buﬀer at pH 7.4. Brains were removed
from the skull and cut into 40μm thick frontal sections on
a microtome with vibrating blade (Leica VT 1000S, Ben-
zheim, Germany) and the sections collected in 0.37% glycine
dissolved in 0.1M phosphate buﬀer at pH 7.4. Primary anti-
bodies used in all experimental groups were raised against
GAP-43, MMP-9, or MMP-2 (Table 2).
Diﬀerent immunocytochemical procedures were em-
ployed. For visualizing GAP-43 in AVCN, free-ﬂoating sec-
tions were preincubated in 0.1% Triton X-100, 0.15% H2O2
and5%normalserum,allin0.02MPBSatpH7.4for30min
at room temperature. For MMP-2 and MMP-9 staining, the
same preincubation steps were employed, but Triton X-100
was replaced by dimethylsulfoxide applied in 4 increasing
concentrations of 5, 10, 20, and 40%. Compared to Triton
X-100, dimethylsulfoxide does not penetrate as deeply into
the sections, providing two clearly separable focal planes
for quantitative particle detection. Sections were incubated
with primary antibodies (Table 2) over night at 4◦C. In-
cubation with the matching secondary antibodies (Table 2)
and formation of an avidin-biotin complex (Elite-ABC;
Vector Laboratories, Burlingame, USA) took 1h each and
were followed by staining with 0.05% 3.3-diaminobenzidine
tetrahydrochloride (DAB; Sigma, Taufkirchen, Germany)
and 0.005% H2O2 in 50mM Tris buﬀer at pH 7.2. For
staining of GAP-43 immunoreactivity, 0.3% ammonium
nickel sulphate were added to the DAB solution. Sections
stained for GAP-43 were mounted on gelatin-subbed slides,
air dried, dehydrated in increasing grades of alcohol, and
cover-slipped with Entellan (Merck, Darmstadt, Germany).
Sections stained for MMP-9 and MMP-2 were incubated in
0.1% osmium tetroxide in cacodylic acid buﬀer at pH 7.2 for
4–7min. Sections were then dehydrated in increasing grades
of ethanol and ﬂat-embedded in epon (Embed-812, Science
Services, M¨ unchen, Germany), supporting morphological
integrity. After hardening of the resin, areas of interest
were photographed and selected for further analyses under4 Neural Plasticity
the light microscope. Sections were reembedded in gelatin
capsules and cut in a transverse plane into 0.5μm thick sem-
ithinsectionsusinganultramicrotome(Reichert-JungUltra-
cut, Vienna, Austria). These sections were mounted on glass
slides, air dried, and cover-slipped with Glycergel (Dako,
Carpinteria, Calif, USA).
To verify the speciﬁcity of all primary antibodies used,
negative controls were run by omitting the primary antibod-
ies in the corresponding incubation step (Figures 1(j), 1(k),
and 4(a) inset). Speciﬁcity of the antibody raised against
MMP-9 was additionally veriﬁed by preincubation with
MMP-9 peptide for 2 hours at room temperature before
exposing sections for immunohistochemical staining as de-
scribed before. An equivalent product was unavailable for
MMP-2. The failure of staining was equally obvious after
these embedded sections were cut to be analyzed as semithin
sections.
2.5. Nissl Staining. Brain sections destined for Nissl staining
were washed in 0.02M PBS at pH 7.4, mounted on gelatin-
coated glass slides, and air dried. They were then defatted in
alcohol, incubated in cresyl violet (Chroma, Stuttgart, Ger-
many, 1A396; 1% in distilled water) for 2min, dehydrated
in increasing grades of ethanol, cleared in xylene, and cover
slipped with Entellan.
2.6. Quantitative Data Acquisition. Photographs were taken
through a ×5o ra×100 objective with a digital camera
(AxioCam, Zeiss, Jena, Germany) at 8bit gray tone depth.
Foreachtypeofstaining,incubationparameters,microscope
settings, exposure times, and global rendering of the pho-
tographs were held strictly constant across all experiments.
We determined the overall staining level of GAP-43 im-
munoreactivity in AVCN by gray tone means in ×5 pho-
tographs (Figure 4) using Photoshop CS (Ver. 8, Adobe, San
Jose, Calif, USA). Analysis of heterogeneous GAP-43 staining
was achieved by measuring gray tone means in two ﬁelds of
equal size, placed in AVCN so that one ﬁeld lied in the region
with the faintest staining and the other in the region with
the strongest staining (Figure 4(f)), avoiding marginal zones
of AVCN. In sections showing homogeneously distributed
GAP-43 immunoreactivity across AVCN and in controls
(Figures 4(a)–4(e)) test ﬁelds where centered in the dorsal
and ventral half of AVCN, respectively. Staining intensities
weredeterminedinAVCNonbothsidesofthebrainstemand
left-to-right or ipsilateral-to-contralateral ratios or ratios for
paired test ﬁelds within the ipsilateral AVCN were calculated.
For MMP-9 and MMP-2, two diﬀerent strategies for
quantitative data acquisition were followed. In the ﬁrst, den-
sitiesofimmunoreactiveparticlesinneuronalcytoplasmand
neuropil of AVCN were detected with analySIS (Soft Imaging
System GmbH, M¨ unster, Germany), setting thresholds of
graytonedetectionratherhighandstrictlyconstantforevery
×100 photograph of semithin sections stained for MMP-9 or
MMP-2,respectively(Figure 2(a)).Semithinsectionscontain
immunoreactive particles in only one focal plane, allowing
their unimpaired quantiﬁcation (Figure 2(c)). After photo-
graphic documentation of the ﬁrst 1 to 3 semithin sections
cut (Figure 2(a)), cover-slips were removed and the sections
counterstained with methylene blue-azure (1% azure II in
distilled water and 1% methylene blue (Merck, Darmstadt,
Germany, 9211 and 6045, resp.) in borax, mixed to equal
parts) to visualize boundaries of cell bodies and nuclei
(Figure 2(b)).Sectionswerethencover-slippedwithEntellan
and photographs of the same locations as already docu-
mented were taken. It was then possible to outline 3 regions
of interest (ROIs), aiming to detect migrations of MMP-9
and MMP-2 positive particles from the cytoplasm into the
surrounding neuropil of AVCN neurons, if they occur. The
ﬁrst ROI outlined the cytoplasm of neurons near their cell
nucleus(ROI1).ThesecondROIoutlinedthecytoplasmnear
the plasma membrane (ROI2). If intracellular movements of
MMPs towards the plasma membrane occurred, we should
be able to detect them by comparing staining in these ROIs
at diﬀerent postoperative points in time. A third ROI (ROI3)
was positioned to cover the neuropil immediately surround-
ing neuronal somata (Figure 2(b)) to determine if there
is an increase of the respective MMP in pericellular regions
over postlesional time. ROI3 was oriented along the cutting
edge of the sections to prevent errors in particle detection
due to decreasing DAB-staining intensity in section depths
beyond reach of primary antibody diﬀusion (Figures 2(b)
and 2(c)). Neurons were distinguished from glia by size and
morphology. For statistical data acquisition, all neurons with
clearly visible nucleus and cell boundary were taken into
account. This study does not distinguish between diﬀerent
types of neurons. ROIs identiﬁed after counterstaining were
assignedtotheappropriatephotographsofsemithinsections
andusedtodeterminestainingdensityofMMP-9andMMP-
2 immunoreactivity. Left-to-right or ipsilateral-tocontralat-
eral ratios of particle densities in AVCN were calculated.
Knowing that MMP-9 and MMP-2 particle density in
semithin sections signiﬁcantly decreased in the cytoplasm
of AVCN neurons following deaﬀerentation (Figure 2), we
used the staining intensity of MMP-9 and MMP-2 in the
cytoplasm of AVCN neurons in 40μm thick ﬂat-embedded
sections to identify possible transcellular movements of
eitherMMPduetodeaﬀerentation.Inthesecondstrategyfor
quantitative data acquisition gray tone means were deter-
mined in the cytoplasm of AVCN neurons stained for MMP-
9 or MMP-2 (Figure 1(e)) in photographs of ﬂat-embedded
sections taken with an ×100 objective. Left-to-right or ipsi-
lateral-to-contralateralratiosofstainingintensities(Figure 6)
and the ratios of diﬀerently stained ﬁelds within the ipsilat-
eral AVCN (MMP-2 only) were calculated (Figure 7).
StatisticalanalysiswasdoneusingPrism4(GraphPad554
Software, Inc., La Jolla, Calif, USA). Signiﬁcant diﬀerences
between groups of measurements were determined by ap-
plying one-way analysis of variance (ANOVA) followed by
Newman-Keuls post test or, if applicable, with two-tailed
Student’s t-test. Signiﬁcance levels were indicated as ∗∗∗P<
0.001, ∗∗P<0.01, or ∗P<0.05. Signiﬁcance levels indicated
by # in the ﬁgures identify signiﬁcant diﬀerences against the
control level.Neural Plasticity 5
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Figure 1: Time course and distribution of MMP-9 and MMP-2 realignments in AVCN on the side of cochlear ablation (CA), shown
in 40μm thick sections stained with DAB and ﬂat embedded in epon. (a) In AVCN of control animals, numerous neurons were
strongly immunoreactive for MMP-9 in their cytoplasm (arrows). (b and c) By POD1 and POD3, MMP-9 immunoreactivity decreased
in the cytoplasm of most neuronal somata. Beaded collars of MMP-9 immunoreactive particles emerged close to the plasma membrane
(arrowheads). (d) By POD7, the pattern of MMP-9 staining has almost returned to control level (a). (e) MMP-2 was strongly expressed
in the cytoplasm of AVCN neurons in control animals. The white line indicated around the cytoplasm of one neuron shows the sample
ﬁeld for quantitative analysis of MMP-staining intensity in neuronal cytoplasm used to obtain the data shown in Figures 6 and 7(e). (f)
By POD1, only marginal changes in MMP-2 staining were seen. A derangement seen in tissue texture is caused by disintegrating auditory
nerve ﬁbers. (g) By POD3, the content of MMP-2 in cytoplasm of AVCN neurons slightly decreased. (h) This decrease continued towards
POD7 when beaded collars of MMP-2 positive particles became visible in direct vicinity to the cell’s plasma membrane (arrowheads). (i)
and (h) Neutralization of the primary antibody prior to the staining procedure (i) and omission of the primary antibody against MMP-9
(j) veriﬁed speciﬁcity of the immunostaining. (k) Omitting incubation with antibody raised against MMP-2 resulted in failure of staining.
Global contrast adjustment was identical for all photographs in this ﬁgure. Scale bar: 20μm.6 Neural Plasticity
Figure 2: Semithin sections through AVCN stained for MMP-9 and MMP-2 immunoreactivity following cochlear ablation, and their
quantitative evaluation. (a) By POD7, MMP-2 immunoreactivity showed up as particles. (b) Counterstaining of the same section with
methylene blue, visualizing cellular boundaries. Lines indicate the regions of interest (ROI) sparing the cell nucleus (nu). (c) Same section as
in (a) with the superimposed ROIs. Particles detected by computer-aided image analysis are indicated in red. Scale bar for (a)–(c) 20μm. (d)
Subcellular redistribution of MMP-9 immunoreactive particles in AVCN neurons in control animals (ctrl) and at POD1, 3 and 7 following
cochlear ablation. Bars indicate particle density in ROI1 and ROI2. ns designates insigniﬁcant changes within ROI2 at any time. (e), (f)
Changes in MMP-9 particle density in cytoplasm (e) and neuropil (f) of AVCN neurons in controls (ctrl) and by POD1, 3 and 7 following
cochlear ablation. Bars indicate left-to-right (l/r) or ipsilateral-to-contralateral (i/c) ratio of particle density. (g) Subcellular redistribution of
MMP-2 immunoreactive particles within the cytoplasm of AVCN neurons in control animals (ctrl) and by POD1, 3 and 7. (h), (i) Changes
in MMP-2 particle density in cytoplasm (h) and neuropil (i) of AVCN neurons in control animals (ctrl) and by POD1, 3 and 7 following
cochlear ablation.Neural Plasticity 7
3. Results
3.1. Time Course of MMP-9 Realignments in AVCN Following
Cochlear Ablation. In AVCN of the normal adult rat, MMP-
9 expression was high in the cytoplasm of neuronal cell
bodies(Figure 1(a)).LevelsofMMP-9werelowerintheneu-
ropil, resulting in their distinct appearance (Figure 1(a)).
Following cochlear ablation, MMP-9 expression decreased in
many neuronal somata as soon as by POD1 (Figure 1(b)).
At the same time, numerous small MMP-9 immunoreactive
particles emerged as beaded collars around the neuronal
plasma membrane (Figure 1(b)). Whereas these eﬀects were
strong by POD1 and POD3 (Figures 1(b) and 1(c)), the
pattern of MMP-9 staining almost returned to the preoper-
ative condition by POD7 (Figure 1(d)). Despite the massive
derangement of the tissue caused by auditory nerve degen-
eration, the overall staining density in these ﬂat-embedded
sections remained largely unchanged during the postopera-
tive period examined (Figures 1(a)–1(d)). Negative controls
of osmicated, ﬂat-embedded sections showed now staining
at all (Figure 1(j)), neither did sections incubated with the
neutralized primary antibodies (Figure 1(i)).
To test the hypothesis that MMP-9 undergoes redistri-
bution rather than a locally varying degradation and reex-
pression, we determined the density of MMP-9 immunore-
activity in semithin sections through AVCN quantitatively
(Figures2(a)–2(c)).Insectionsofcontroltissue,MMP-9was
foundtobeunevenlydistributedinthecytoplasmofneurons
(Figure 2(d)). The majority of MMP-9 immunoreactive par-
ticles was located in ROI1 near the cell nucleus, while the
rest was located in ROI2 close to the plasma membrane
(Figure 2(d)). This ratio was inverted by POD1 (Figure 2(d))
due to a signiﬁcant decrease of the particle density in
ROI1. Particle density in ROI2 did not change (Figure 2(d)).
Measuring the density in the entire cytoplasm, we found a
strong net decrease of MMP-9 immunoreactive particles by
POD1(Figure 2(e))comparedtocontrollevels(Figure 2(e)).
At the same time, MMP-9 particle density rose signiﬁcantly
in the neuropil surrounding the neurons (Figure 2(f)). By
POD3,theintracellulardistributionofMMP-9seenatPOD1
persisted (Figure 2(d)), with a slight net increase of the par-
ticle density in the entire cytoplasm (Figure 2(e)). Staining
of the neuropil remained unchanged compared to POD1
(Figure 2(f)). By POD7, MMP-9 particle density in ROI1
increased signiﬁcantly (Figure 2(d)), returning to control
levels. Similarly, particle density in the neuropil decreased to
return to control levels (Figure 2(f)). No change in particle
density was detectable in ROI2 at any survival time.
3.2. Time Course of MMP-2 Realignments in AVCN Following
Cochlear Ablation. Similar to MMP-9, MMP-2 was realigned
in AVCN as a consequence of sensory deaﬀerentation. In the
normal adult rat, MMP-2 showed a staining pattern remi-
niscent of that seen with MMP-9. Neuronal cell bodies were
strongly labeled, standing out against a faintly labeled neu-
ropil(Figure 1(e)).ComparedtoMMP-9,MMP-2responded
more sluggishly to sensory deaﬀerentation (Figures 1(f)–
1(h)). By POD1, changes in the pattern of MMP-2 staining
were barely visible (Figure 1(f)), but the level of MMP-2
in the cytoplasm of neurons had slightly decreased by
POD3 (Figure 1(g)). Towards POD7, the decrease grew more
pronounced (Figure 1(h)). At that time, neuronal cell bodies
were left with low levels of MMP-2 immunoreactivity in
their cytoplasm. Notably, MMP-2 staining now revealed
beaded collars close to the neuronal plasma membrane
(Figure 1(h)), that is, at a time when most such collars
visible under MMP-9 staining (Figures 1(b) and 1(c)) had
disappeared. As for MMP-9, the overall staining density
remained essentially unchanged after cochlear ablation
(Figures 1(e)–1(h)). Negative controls of osmicated, ﬂat-
embeddedsectionsfailedtorevealanystaining(Figure 1(k)).
To test the hypothesis of a redistribution of MMP-2
in AVCN following its sensory deaﬀerentation, the density
of MMP-2 immunoreactivity (Figures 2(a)–2(c)) was deter-
mined in semithin sections (Figures 2(g)–2(i)). In the AVCN
of control animals, MMP-2 was unevenly distributed in
the cytoplasm of neurons (Figure 2(g)), much in the same
manner as MMP-9. While the majority of MMP-2 immuno-
reactive particles was located in ROI1 near the cell nucleus,
the rest was located in ROI2 close to the plasma membrane
(Figure 2(g)). Following cochlear ablation, particle density
of MMP-2 immunoreactivity decreased gradually near the
cell nucleus (ROI1), whereas it remained on control level in
ROI2 at all survival times (Figure 2(g)). The gradual decrease
of MMP-2 immunoreactivity in cytoplasmatic ROI1 from
POD1 over POD3 towards POD7 (Figure 2(g)) resulted in
an inversion of the ratio of MMP-2 particle densities in
cytoplasmatic ROI1 and ROI2 (Figure 2(g), POD7). Parallel
to the net decrease in the cytoplasm of AVCN neurons
(Figure 2(h)), the density of MMP-2 positive particles rose
progressively in the neuropil towards POD7 (Figure 2(i)),
suggesting a reallocation of MMP-2 from intracellular to ex-
tracellular realms in AVCN due to the loss of cochlear input.
3.3. KA Injections. In order to determine if there are causal
dependenciesratherthanmerecoincidencesamongthedeaf-
ferentation-dependent expression and redistributions of
MMP-9 and MMP-2 on the one hand, and the reinnervation
associated with GAP-43 immunoreactivity on the other
hand, KA was stereotaxically injected into VNTB prior to
cochlear ablation, destroying neuronal cell bodies residing in
this nucleus [12]. Nissl staining served to determine success
and degree of the excitotoxic lesion. Conspicuously large
neuronal cell bodies characterize VNTB (Figures 3(a) and
3(b)). A total loss of neuronal somata in VNTB indicated a
completelesionofVNTBneurons(Figures3(c)and3(d)).In
several experiments, however, due to an oﬀ-center KA injec-
tion, neurons were destroyed only in part of VNTB while
those in other parts survived the treatment (Figures 3(e)
and 3(f)). Control injections of PBS instead of KA into
VNTB failed to induce a notable reduction of Nissl-stained
cell bodies (not illustrated).
3.4. Patternof GAP-43 Expression FollowingCochlear Ablation
withorwithoutPrecedingVNTBLesion. Ahealthyratbrains-
tem is bilaterally symmetric, and staining of tissue in AVCN
for any antigen should result in a left-to-right density ratio8 Neural Plasticity
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Figure 3: Nissl staining used to document eﬀectiveness and extent of KA injection into VNTB. (a, b) In the superior olivary complex of
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parts of VNTB (f). In the case shown in (e), medially residing neurons survived the injection (arrows) while most of the laterally residing
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Figure 4: GAP-43 expression in AVCN after complete or incomplete VNTB lesion and subsequent cochlear ablation. (a) Little GAP-43
expressionwasfoundinAVCNofcontrolanimals.Inset:nostainingoccurredwhenomittingtheprimaryantibody.(b,c)Followingcochlear
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VNTB with cochlear ablation (KAcL + CA) led to near-complete failure of GAP-43 expression in AVCN. (f) In cases with incomplete lesion
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all photographs shown. (g) Staining intensity of GAP-43 immunoreactivity in the AVCN given as gray tone mean. Bars indicate ipsilateral-
to-contralateral ratio (i/c) for cases with CA alone and KAcL + CA at POD3 and POD7 following cochlear ablation. Asterisks indicate
signiﬁcant diﬀerences among groups, number signs (hash symbols) indicate signiﬁcant diﬀerences against control. (h) Heterogeneity of
GAP-43 staining in ipsilateral AVCN after CA, KAcL + CA, and KAiL + CA. Bars indicate ratio between the strongest and faintest GAP-43-
stained region within the AVCN.10 Neural Plasticity
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Figure 5: Time course of the distribution of MMP-9 and MMP-2 following combination of KA injection completely lesioning VNTB and
cochlear ablation (KAcL + CA). (a)–(c) The distribution of MMP-9 showed no diﬀerences compared to the pattern following cochlear
ablation alone (Figure 1(a)–1(d)). Compared to control animals (a), the cytoplasm of AVCN neurons (arrows in (a)) have lost MMP-
9 by POD3 (b) but regained it till POD7 (c). Beaded collars close to the plasma membrane were particularly prominent around POD3
(arrowheads in (b)). (d–f) As in case with cochlear ablation alone (Figures 1(e)–1(h)), the cytoplasm of AVCN neurons partially lost their
MMP-2 immunoreactivity by POD3 (e). By POD7, MMP-2 immunoreactivity in cytoplasm of neurons was almost back to control level (d)
again (f). Scale bar: 20μm. Global contrast adjustment was identical for all photographs in this ﬁgure.Neural Plasticity 11
of close to 1. Neither in normal animals (P = 0.41 for
left-versus right-staining density) nor in animals receiving a
unilateral PBS or KA injection alone (P = 0.49 and P = 0,45
for left versus right staining density, resp.) did we ﬁnd an
asymmetry of GAP-43 staining in AVCN. In any of these
cases, GAP-43 staining was low (Figure 4(a)), conﬁrming a
previous study [12]. Negative controls omitting the primary
antibodiesdidnotshowanystaining(Figure 4(a),inset).Asa
consequence of cochlear ablation, GAP-43 staining emerged
in a growing network of ﬁne ﬁbers and boutons and rose
signiﬁcantly in staining density in the ipsilateral AVCN as
soon as by POD3 (Figures 4(b) and 4(g), left black bar). By
POD7, GAP-43 staining was strong (Figures 4(c) and 4(g),
right black bar), with ﬁbers and boutons now prominent. As
cochlea and spiral ganglion were always completely ablated
in the present study (for incomplete cochlear lesions cp. [5]),
GAP-43 immunoreactivity was found in evenly distributed
ﬁber networks throughout the ipsilateral AVCN in Group 3
(Figures 4(b), 4(c), and 4(h), black bars).
When KA was unilaterally injected to fully destroy VNTB
before ablation of the cochlea on the other side, the rise of
GAP-43 immunoreactivity failed to occur or was strongly
reduced at any time following cochlear lesion (Figures 4(d)
and 4(e)). Correspondingly, the ipsilateral-to-contralateral
ratio of GAP-43-staining intensity remained close to 1
(Figure 4(g)). When the population of VNTB neurons was
incompletely destroyed (Figure 3(e)), a heterogeneous or
patchy pattern of GAP-43 staining emerged in AVCN after
cochlear ablation (Figure 4(f)), reﬂecting a partially intact
projection from VNTB to AVCN. A patchy distribution in-
stead of an area-wide moderation of GAP-43 immunoreac-
tivity indicated that some topographic order must exist in
this projection. A comparison of gray tone means of regions
darkly stained for GAP-43 with regions showing less or no
GAP-43 staining, both in the AVCN ipsilateral to cochlear
ablation, revealed a signiﬁcant diﬀerence (P<0.01 and
P<0.001 for POD3 and POD7, resp.; Figure 4(h), shaded
bars).
3.5. Time Course of MMP-9 Realignment Following Cochlear
Ablation with Preceding Complete Lesion of VNTB. When
the pattern of MMP-9 immunoreactivity was studied after
cochlear ablation preceded by complete destruction of the
contralateral VNTB, no diﬀerences were observed compared
to the expression pattern following cochlear ablation alone
(compare Figures 1(c), 1(d) with 5(b), 5(c)). Apparently,
axonal growth associated with GAP-43 in AVCN had no
eﬀect on the deaﬀerentation-induced development of MMP-
9 realignment in AVCN. Neuronal cell bodies that were rich
in MMP-9 before cochlear ablation had lost much MMP-
9 immunoreactivity by POD3 (Figure 5(b)) but returned to
controllevelsbyPOD7(Figure 5(c))independentofthestate
of VNTB.
3.6. Time Course of MMP-2 Realignment Following Cochlear
Ablation with Preceding Complete Lesion of VNTB. By sharp
contrast, a preceding lesion of the contralateral VNTB sub-
stantially altered the dynamics of MMP-2 actuated by
cochlearablation(Figures5(d)–5(f)).Thischangewasnotyet
apparent by POD3 but obvious by POD7. Lesioning VNTB
before the cochlea caused MMP-2 expression to increase in
the cytoplasm of AVCN neurons at POD7 (Figure 5(f)) to
a level that was indistinguishable from control cases (Figure
5(d)), so as if no cochlear ablation had occurred.
3.7. Statistical Evaluation of Time Course and Distribution of
MMP-9 and MMP-2 Following Cochlear Ablation without or
with Preceding Complete Lesion of VNTB. To verify statistical
signiﬁcances of the observations detailed in Sections 3.5 and
3.6, staining densities for MMP-9 and MMP-2 immunore-
activity in the cytoplasm of neurons after cochlear ablation
without or with a preceding complete contralateral lesion
of VNTB were quantiﬁed by measuring gray tone means.
Possible variabilities in staining conditions among cases were
leveled by calculating the ratio of ipsilateral-to-contralateral
staining intensities.
By POD3, MMP-9 staining was signiﬁcantly lowered
compared to controls (Figure 6(a), left bar). This decrease
occurred independent of whether VNTB was intact or not
(Figure 6(a), second bar). By POD7, MMP-9 staining has
regainedcontrollevels(Figure 6(a),thirdbar),againwithout
being inﬂuenced by the state of VNTB (Figure 6(a),f o u r t h
bar). MMP-2 staining has decreased by POD3 compared
to control levels (Figure 6(b), left bar). As for MMP-9 this
happened irrespective of the condition of VNTB (Figure
6(b),secondbar).UnlikeMMP-9,however,MMP-2staining
further decreased towards POD7 after cochlear ablation
(Figure 6(b), third bar), provided that the contralateral
VNTB was intact. In cases of VNTB lesioning, MMP-2 stain-
ing rebounded to control levels (Figure 6(b),f o u r t hb a r ) .
3.8. Distribution of MMP-2 in the Ipsilateral AVCN Follow-
ing Cochlear Ablation with Preceding Incomplete Lesion of
VNTB. Cases with an incomplete VNTB lesion opened the
possibility for a local analysis of the relationship between
MMP-2 realignment and reinnervation as indicated by GAP-
43 expression. We noted that the characteristic changes in
the pattern of MMP-2 staining seen by 7 days after cochlear
ablation occurred only in regions of AVCN where GAP-43
positive ﬁbers have emerged at high density (Figure 7). In
favorable cases, a sharp border between GAP-43 rich and
GAP-43 poor regions was observed in AVCN (Figure 7(b)).
Evaluating staining patterns in pairs of adjacent sections, the
heterogeneity of GAP-43 staining was faithfully matched by
MMP-2 staining (Figures 7(a), 7(c), and 7(d)). Quantitative
analysis(Figure 7(e)revealedasigniﬁcantdiﬀerencebetween
the staining intensities of neuronal cytoplasm for MMP-
2 in regions corresponding to strong GAP-43 staining
(Figure 7(c)) and weak GAP-43 staining (Figure 7(d)).
4. Discussion
As a cochlear ablation induces a total sensory deaﬀerenta-
tion in the CN, the ﬁrst central relay of the ascending audi-
tory system, its tissue is reorganized in complex ways.12 Neural Plasticity
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Figure 6: Statistical evaluation of the modulation of MMP-9- and MMP-2-staining intensity in the cytoplasm of AVCN neurons following
cochlear ablation (CA) with or without a preceding complete lesion of VNTB (KAcL). (a, b) Bars indicate ipsilateral-to-contralateral ratios
(i/c) of gray tone means of MMP-9 (a) and MMP-2 (b) measured in the cytoplasm of AVCN neurons (test ﬁeld indicated in Figure 1(e))
following cochlear ablation or combination of KA injection with complete lesion of VNTB with cochlear ablation (KAcL + CA). The dashed
lines mark a i/c ratio of 1, indicating control level. Whereas VNTB lesions have no inﬂuence on the loss and regain of MMP-9 from neuronal
cytoplasm after cochlear ablation, MMP-2 levels return to control level by POD7 only if the reinnervation is prevented. Asterisks indicate
signiﬁcant diﬀerences among groups, number signs (hash symbols) indicate signiﬁcant diﬀerences against control.
Obviously, a massive degeneration of sensory ﬁbers and
their presynaptic endings occurs that has a quick onset
a n di sc o m p l e t e dw i t h i n1 0d a y s[ 32]. As this happens,
reorganization gradually takes over from degeneration. The
stages of reorganization encompass diﬀerent morphological
and molecular realignments [11], among them extensive
changes to the ECM. We wondered how MMP-9 and MMP-
2, key enzymes in ECM modulation, are involved in these
processes and how this involvement might be regulated.
The major ﬁndings of the present study are threefold.
First, following cochlear ablation, MMP-9 and MMP-2 are
realigned in AVCN, and these realignments appeared to be
speciﬁcally associated with degeneration and reinnervation,
respectively. Second, the deaﬀerentation-dependent arrival
of GAP-43 positive ﬁbers in AVCN had no eﬀect on changes
of MMP-9, neither in the early phase after cochlear ablation
when auditory nerve ﬁbers and their synaptic terminals in
AVCN degenerate, nor in the subsequent phase of reinner-
vation when synaptogenesis takes place. Third, level and
pattern of MMP-2 were restored to control level by POD7 if
reinnervationwasprevented.Theseobservationssuggestthat
MMP-9 tends to be associated to neuropil reorganization
related to ﬁber and terminal degeneration, whereas MMP-2
is predominantly involved in assisting reinnervation and
synaptogenesis.
4.1. Association of MMP-9 and MMP-2 with Tissue Dynam-
ics in Diﬀerent Postlesional Phases. Our data suggest that
following deaﬀerentation of AVCN, overall expression levels
of neither MMP-9 nor MMP-2 were changed. Instead, both
MMPs were reallocated in numerous AVCN neurons from
cytoplasmic regions near the nucleus towards the plasma
membrane, and then secreted out into the surrounding neu-
ropil. This we showed quantitatively in osmicated semithin
sections. Osmication was done with minimum concentra-
tion of osmium and incubation time and therefore did not
mask the immunoreactive structures to be analyzed.
Following cochlear ablation, MMP-9 availability and dis-
tribution in AVCN were maximally changed as soon as by
POD1andreturnedtocontrollevelstillPOD7(Figures1(a)–
1(d), 2(d)–2(f)). These realignments of MMP-9 as intra-
andtranscellularmigration(Figure 2)occurredearlyenough
to be temporally associated to degenerative events, that is,
degeneration of axons and axon terminals as well as oligo-
dendrocytes.
Manipulation of the projection from VNTB to AVCN
by KA injection failed to aﬀect the deaﬀerentation-induced
development of availability and distribution of MMP-9, in-
dicating independency of MMP-9 from the subsequent re-
organization of the neural network texture as indicated by
the emergence of GAP-43 positive axons and axon terminals
in AVCN. Together with the early onset of changes, the in-
dependence of MMP-9 from VNTB integrity and AVCN
reinnervation suggest that this metalloproteinase, in the
system studied here, acts in the context of degeneration.
MMP-9 function has been implicated in synaptic plas-
ticity and long-term potentiation by extracellular proteolysisNeural Plasticity 13
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Figure 7: Distribution of MMP-2 in the ipsilateral AVCN on POD7 after incomplete lesion of VNTB due to KA injection followed by
cochlear ablation. (a) Section through AVCN stained for MMP-2, showing a distinct border in the staining pattern of MMP-2 (black line).
Frames indicate regions shown at higher magniﬁcation in (c) and (d). Arrowheads indicate blood vessels also found in the adjacent section
shown in (b) stained for GAP-43. (b) In a section through AVCN parallel to the one shown in (a), GAP-43 expression shows a heterogeneity
as well (black line) which closely corresponded to the border seen in (a). (c), (d) Photographs at high magniﬁcation taken of MMP-2
immunoreactivity in regions of AVCN corresponding to high expression level of GAP-43 (RGAP−43+)a n dl o wt on oe x p r e s s i o no fG A P -
43 ((RGAP−43−), respectively. Scale bar: 200μm for (a), (b); 20μm for (c), (d). (e) Quantitative evaluation of MMP-2-staining intensity in
cytoplasm of local populations of AVCN neurons based on photographs like those shown in (c) and (d).
[33–36]. However, our data failed to hint at a direct involve-
ment of MMP-9 in synaptogenesis following deaﬀerentation
of AVCN due to cochlear ablation.
The onset of MMP-2 realignment was slightly delayed
against that of MMP-9 and proceeded towards POD7 when
MMP-9 has already returned to normal. This time course
does not match well with degeneration [32] but corresponds
temporally to the deaﬀerentation-dependent reinnervation
of AVCN by ﬁbers of MOC neurons identiﬁed by their
contents of GAP-43 (Figures 1(e)–1(h), 2(g)–2(i), and 4(a)–
4(c)). When GAP-43 staining level is maximal in the deaf-
ferented AVCN, many neuronal somata lost virtually all of
their MMP-2 (Figure 1(h)). More importantly, when axons
were prevented from reinnervating central parts of AVCN,
MMP-2stainingreturnedbacktothepredeaﬀerentationpat-
tern by POD7. This indicates a causal dependency of the
progression of MMP-2 realignment on the reinnervation of
AVCN neurons by GAP-43 containing ﬁbers and boutons.
4.2. Consequences of VNTB Lesions on GAP-43 Expression
in CN. In spite of a constant volume and concentration
of KA injected into VNTB, the radius of the injection site
varied considerably among cases, an observation also made
for other cerebral systems in which KA was used (e.g., [37]).
In the present study we turned this variability to our advan-
tage, analyzing lesions of varying size and position for their
systematic consequences on GAP-43 staining in AVCN fol-
lowing cochlear ablation. A complete lesion of VNTB that
destroyed all neurons potentially innervating central AVCN
following cochlear ablation held GAP-43 expression on con-
trol level despite a preceding cochlear ablation. The hetero-
geneous distribution of GAP-43 immunoreactivity in AVCN
following incomplete lesions of VNTB was shown to be
related to the survival of large VNTB neurons likely to be
MOC neurons projecting to AVCN by axon collaterals [15].
The fact that the surviving subpopulation of VNTB neurons
does not raise GAP-43 staining across the entire AVCN but
only in distinct regions reveals an independent look on the
topographical organization of this projection already sug-
gested by tracing studies [14, 38]. Our ﬁndings suggest that14 Neural Plasticity
laterally positioned neurons project to medial AVCN and
medially positioned neurons to lateral AVCN, both on the
opposite side of the brainstem.
4.3. Contribution of MMP-9 and MMP-2 to Tissue Dynamics
in Diﬀerent Postlesional Phases. We found evidence to relate
M M P - 9f u n c t i o ni nA V C Nt ot h ed e g e n e r a t i v ep h a s ef o l -
lowing cochlear ablation. Reeves et al. [39] suggest a role
of MMP-9 in the deaﬀerentation/sprouting cycle in hippo-
campus following unilateral entorhinal cortex lesion. They
found that rats receiving an MMP-9 inhibitor failed to
develop the capacity for long-term potentiation and showed
persistent cellular debris of degenerating terminals not fol-
lowed by axonal sprouting and synaptogenesis, as was the
case in control experiments. Zhang et al. [40]s p e c u l a t e
that upregulation of MMP-9 following nerve injury may be
part of the tissues’ eﬀort to accomplish synaptic remodeling.
This is in line with Reeves et al. [39] who showed that no
regeneration is initiated if the degenerative phase remains
incomplete due to the absence of MMP-9 activity. Con-
tributions of MMP-9 to shape tissue structure following
nerve degeneration appear to be part of the prerequisites for
reinnervation and synaptogenesis.
Changes in MMP-2 realignment appeared to be under-
way before the deaﬀerentation-dependent induction of rein-
nervation of AVCN. Through proteolytic cleavage of recep-
tors, adhesion molecules, and the ECM lattice, attachment
sites for new synapses need to be exposed [39, 40]. The
onset of MMP-2 secretion before reinnervation of AVCN
suggeststhatMMP-2mediatedremodelingofthepericellular
environment prepares the tissue for a reactive synaptogenesis
to occur [39, 40].
The essential ﬁnding of the present study is that changes
in the distribution of MMP-2 after POD3 depend on the
presence of GAP-43 containing axons, growth cones, or
nascentpresynapticendings,heraldingreinnervationinclud-
ing synaptogenesis. It is known that MMPs are involved
in axonal guidance. For instance, broad-spectrum metal-
loproteinase inhibitors applied in vivo to retinal ganglion
cells led to misguided axons in the developing visual sys-
tem [41]. MMPs have been implicated in modulating the
interactionofgrowthconeguidancecueswiththeirreceptors
through cleavage of their ectodomains [42–44]. Future di-
rections to test the crucial role of MMP-2 in axonal growth
and synaptogenesis could be experiments including speciﬁc
MMP-2 inhibitors or MMP-2 knockouts.
The observations made in our study are consistent with
reports on the implication of MMP-2 in synaptogenesis and
synapse remodeling through cleavage of ECM proteins like
laminin [45] and brevican [46], as well as growth factors
like TNF-α [47], and brain derived neurotrophic factor [48],
all of which have profound eﬀects on synaptic plasticity and
synaptogenesis (for review see [25]). Eventually, there seems
to be a reciprocal relationship between induction of axonal
growth and reactive synaptogenesis on the one hand and
the reshuﬄing of MMP-2 on the other. Whereas induction
of reinnervation turned out to be necessary to maintain the
MMP-2 response over the phase of AVCN reinnervation,
MMP-2 appears to facilitate GAP-43-directed axonal growth
and synaptogenesis by molding ECM molecules, allowing
growing axons to permeate the tissue and ﬁnd their targets.
Ad i ﬀerential functional association of MMP-9 and
MMP-2 is also suggested by the type and the temporal suc-
cession of speciﬁc immunoreactive structures. Collars of
particlesspatiallyassociatedtotheplasmamembraneofneu-
r o n a lc e l lb o d i e si nA V C Nw e r es e e nt od e v e l o pa f t e rd e a f -
ferentation by use of antibodies either raised against MMP-9
(Figures1(b)and1(c))orMMP-2(Figure 1(h)).Thesebead-
ed collars were reminiscent of synaptophysin-stained collars
knowntorevealringsofpresynapticendings[4].Whendeaf-
ferentation caused many presynaptic endings to perish [49],
MMP-9 positive collars arose quickly, suggesting action re-
lated to degradation of decaying presynaptic endings. By
contrast, MMP-2-positive collars were present by POD7
when MMP-9 collars had already disappeared (Figures 1(d),
1(h)). By that time, neurons of AVCN have developed collars
ofGAP-43-positivepresynapticendings[4,10].Thissuggests
action of MMP-2 speciﬁcally related to the formation of new
synaptic contacts. The absence of MMP-2-positive collars in
cases when synaptogenesis in AVCN is prevented by VNTB
lesion lends strong support to this reading of our observa-
tions.
Perineuronal nets are specializations of the ECM that
enwrap neuronal cell bodies, serving to resist structural
changes to existing synaptic contacts [50, 51]. Among the
neuronal populations bearing perineuronal nets are neurons
of the AVCN [52–54]. Foscarin et al. [55]n o t e dar i s eo f
activity of MMP-9 or MMP-2 or both with decreasing integ-
rity of perineuronal nets. This faltering of perineuronal nets
was induced in the deep cerebellar nuclei of mice that were
exposed to enriched environments, over-expressing GAP-43
in cerebellar Purkinje cells. Again, these observations do not
excludethepossibilitythatMMP-9andMMP-2diﬀerentially
contribute to synaptogenesis, the one perhaps preparatory,
the other aiding, that takes place in the adult mammalian
brain upon nerve injury or leaning.
4.4. Conclusions. Our data suggest MMP-9 and MMP-2 to
move out of neuronal cell bodies of the AVCN following
its total sensory deaﬀerentation by cochlear ablation. We
showed that the reinnervation taking place after auditory
nerve degeneration is essential to maintain and promote
changes in distribution and availability of MMP-2, but not
of MMP-9. In our experimental model, MMP-9 function
is straightforwardly attributable to nerve and synapse degra-
dation following cochlear ablation, whereas MMP-2, preac-
tivated in AVCN to prepare for reinnervation, is functionally
attributable to a compensatory reorganization of the deaﬀer-
ented neuronal network that includes axonal sprouting and
synaptogenesis.
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